

Original article

A cross-sectional multicentre study of multishell diffusion MRI in multiple sclerosis

Einar A. Høgestøl^{a,b,c,*}, Daniel A. Rinker^a, Ivan Maximov^{b,d,e}, Piotr Sowa^f, Elisabeth G. Celius^{a,c}, Tuva R. Hope^g, Atle Bjørnerud^{g,h,i}, Fuaad M. Sofia^a, Eloy Martinez de las Heras^j, Elisabeth Solana^j, Sara Llufríu^j, Juan Francisco Corral Gamez^k, Julio Alonso Farre^k, Deborah Pareto^k, Sara Collorone^l, Elisabetta Pagani^m, Gabriel Gonzalez-Escamillaⁿ, Sergiu Groppaⁿ, Jaume Sastre-Garriga^o, Àlex Rovira^k, Ahmed Toosy^{l,p}, Massimo Filippi^{m,q,r}, Maria Assunta Rocca^{m,q,r}, Lars T. Westlye^{b,d,s}, Hanne F. Harbo^{a,c}, Mona K. Beyer^{c,f}, on behalf of MAGNIMS study group¹

^a Department of Neurology, Oslo University Hospital, Oslo, Norway

^b Department of Psychology, University of Oslo, Oslo, Norway

^c Institute of Clinical Medicine, University of Oslo, Oslo, Norway

^d NORMENT, Division of Mental Health and Addiction, Oslo University Hospital

^e Department of Health and Functioning, Western Norway University of Applied Sciences, Bergen, Norway

^f Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway

^g Department of Physics, University of Oslo, Oslo, Norway

^h Unit for Computational Radiology and Artificial Intelligence, Oslo University Hospital, Oslo, Norway

ⁱ Department of Psychology, Faculty for Social Sciences, University of Oslo, Oslo, Norway

^j Neuroimmunology and Multiple Sclerosis Unit and Laboratory of Advanced Imaging in Neuroimmunological Diseases (ImaginEM), Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain

^k Section of Neuroradiology, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

^l Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, London, UK

^m Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

ⁿ Department of Neurology, Focus Program Translational Neuroscience (FTN), University Medical Center of the Johannes Gutenberg University, Mainz, Germany

^o Servei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

^p Translational Imaging Group, Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, London, UK

^q Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

^r Vita-Salute San Raffaele University, Milan, Italy

^s KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway

Abbreviations: ADC, apparent diffusion coefficient; BIANCA, brain intensity abnormality classification algorithm; CI, cellularity index; CIS, clinically isolated syndrome; dMRI, diffusion MRI; EDSS, expanded disability status scale; DMTs, disease modifying treatments; DTI, diffusion tensor imaging; DWI, diffusion weighted imaging; EPI, echo planar imaging; FA, fractional anisotropy; HC, healthy control; MAGNIMS, magnetic resonance imaging in multiple sclerosis; MD, mean diffusivity; MRI, magnetic resonance imaging; MS, multiple sclerosis; NAGM, normal appearing grey matter; NAWM, normal appearing white matter; ND, neurite density; NODDI, Neurite Orientation Dispersion and Density Imaging; pwMS, persons with multiple sclerosis; RD, radial diffusivity; rD – FA, FA for restricted diffusion compartment; RSI, Restriction spectrum imaging; SE, spin echo; SMT, Spherical Mean Technique; SW, spatial weighting; TBSS, tract-based spatial statistics; WM, white matter; WML, white matter lesion.

* Corresponding author.

E-mail address: enar.august@gmail.com (E.A. Høgestøl).

¹ The authors are members of the MAGNIMS network (Magnetic Resonance Imaging in MS; <https://www.magnims.eu/>), which is a group of European clinicians and scientists with an interest in undertaking collaborative studies using MRI methods in multiple sclerosis, independent of any other organization and is run by a steering committee whose members are: F. Barkhof, N. de Stefano, J. Sastre-Garriga (Co-Chair), O. Ciccarelli, C. Enzinger, M. Filippi, C. Gasperini, L. Kappos, J. Palace, H. Vrenken, À. Rovira, M.A. Rocca (Co-Chair) and T. Yousry

<https://doi.org/10.1016/j.msard.2025.106435>

Received 18 October 2024; Received in revised form 18 March 2025; Accepted 5 April 2025

Available online 6 April 2025

2211-0348/© 2025 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

ARTICLE INFO

Keywords:

Multiple sclerosis
MRI
Diffusion weighted imaging
Multicentre

ABSTRACT

Background and objectives: White matter (WM) microstructural properties from advanced multishell diffusion MRI (dMRI) have been linked to clinical disability in multiple sclerosis (MS). This multicentre study used multishell dMRI to compute WM metrics and test for differences between people with MS (pwMS) and healthy controls (HCs).

Methods: We included multishell dMRI data from 251 pwMS or clinically isolated syndrome (CIS) (mean age 40.7 years, 72.4 % women, 88.8 % relapsing remitting MS) at six MAGNIMS centres and 543 HCs. Eleven scalar metric maps were estimated from multishell dMRI sequences, based on diffusion tensor imaging (DTI) and restriction spectrum imaging (RSI). The maps were analysed using tract-based spatial statistics (TBSS). The diffusion output was submitted to paired sampled *t*-tests to test for case-control differences and linear regression models to test for associations with Expanded Disability Status Scale (EDSS) scores, while accounting for confounders. In a sub-sample from Oslo, we tested for correlations between EDSS and dMRI metrics within WM lesions.

Results: Significant group differences were found in nine out of eleven dMRI metrics. Linear regression models revealed significant correlations between EDSS and fractional anisotropy (FA) fast ($\beta = -4.54$, $p = 0.01$) and apparent diffusion coefficient (ADC) fast ($\beta = 10.92$, $p = 8.7 \times 10^{-3}$).

Conclusions: Diffusion MRI based on clinically feasible multishell sequences uncovers WM group differences between pwMS and HCs, but only a selection of the advanced multishell parameters were sensitive to disability, and no statistically significant correlations with disability remained after Bonferroni correction.

1. Introduction

The typical white matter (WM) lesions in multiple sclerosis (MS), are shared with many disorders and conditions and lack sensitivity and specificity (Geraldes et al., 2018). The “clinico-radiological paradox”, that MRI characteristics only show modest correlation with disability, may be partly explained by occult injury or damage to normal-appearing white or grey matter (NAWM/NAGM), which often remains undetected (Barkhof, 2002; Lublin et al., 2022). Conventional MRI is unable to delineate the exact neuropathological characteristics of MS lesions (Disanto et al., 2018). Hence, there is a need to develop novel imaging-based biomarkers to improve sensitivity and specificity with respect to the microstructural neuropathological processes and to improve the sensitivity to clinical symptoms and disability (Høgestøl et al., 2019).

By assessing the magnitude and direction of water diffusion in vivo, diffusion MRI (dMRI) allows for visualization and quantification of brain microstructural and physiological properties (Le Bihan, 1995). Diffusion tensor imaging (DTI) has been studied extensively in MS (Cercignani and Gandini Wheeler-Kingshott, 2019; Filippi et al., 2001), however, the interpretation of DTI parameters and other imaging parameters is challenging due to crossing fibres and large voxel constraints (Rovaris et al., 2005). In order to model and delineate the signal contributions from intra- versus extra-cellular water compartments, advanced biophysical models leverage dMRI data obtained across a range of directions and b-values. The b-value is a crucial factor in generating diffusion-weighted images as it reflects the strength and timing of the magnetic gradients applied. Higher b-values indicate stronger diffusion effects and thus, images acquired using a combination of lower and higher b-values may provide greater sensitivity to tissue changes. Advanced dMRI has technical limitations and requirements, long scan times, and the model performance in pathological tissue is unclear (Jelescu et al., 2020).

Several multi-compartment models have been developed, particularly Neurite Orientation Dispersion and Density Imaging (NODDI) (Zhang et al., 2012), the Bayesian approach (Reisert et al., 2017) and Spherical Mean Technique (SMT) (Lakhani et al., 2020). Restriction spectrum imaging (RSI) is another advanced dMRI acquisition technique that characterizes tissue microstructure at a sub-voxel level, by leveraging multiple b-values and directions (White et al., 2013). RSI has been studied in various domains including histology validation, tumour delineation, Parkinson’s disease and normal aging (White et al., 2014; Brunsing et al., 2017; Hope et al., 2019; Beck et al., 2021). It has the advantage of relatively short scanning time (Hagler et al., 2019). RSI has been suggested as an alternative to NODDI in investigation of persons

with MS (pwMS) (Mustafi et al., 2019). One study employed NODDI in a small clinical sample ($n = 5$) (Schneider et al., 2017). Two other studies looked at microstructural abnormalities in cortical lesions and normal appearing grey matter (Preziosa et al., 2022), and the contribution of focal lesions and normal-appearing (NA) tissue microstructural abnormalities to cognitive impairment in MS (Preziosa et al., 2023). Another study applied myelin water and multishell diffusion imaging to quantify the relative damage to myelin and axons among different lesion types, in normal-appearing tissue, and across MS clinical subtypes and healthy controls (HCs) (Rahmanzadeh et al., 2021). One study reported a correlation between disability and RSI parameters among pwMS but did not compare patients to HCs (Sowa et al., 2019). Other studies have also investigated diffusion MRI parameters in pwMS and found clinical correlations and explored disease pathology, both cross sectional and longitudinal, and also in combination with other MRI modalities (York et al., 2022; Yoon et al., 2022; Kato et al., 2022; Schiavi et al., 2023). In summary, there is a focus on advanced dMRI, highlighting its potential to explore the microstructural abnormalities in pwMS.

Our main hypothesis in this study was that applying diffusion tensor and microstructural measures on our multicentre MRI and clinical data may offer novel insights into MS. We hypothesize that applying ComBat harmonization to address site-specific variability in dMRI metrics, followed by a unified post-processing pipeline, enables us to combine data across sites and to differentiate between pwMS and HCs. Secondly, we aimed to assess the sensitivity to disability, measured with the Expanded Disability Status Scale (EDSS), across the dMRI metrics.

2. Materials and methods

2.1. Study design and participants

In this cross sectional retrospective multicentre study of pwMS, we acquired MRI and clinical data from six centres of the Magnetic Resonance Imaging in MS (MAGNIMS) consortium. The centres in alphabetical order: Hospital Clínic, IDIBAPS, Barcelona, Spain; IRCCS San Raffaele Scientific Institute, Milan, Italy; Oslo University Hospital, Oslo, Norway; University Medical Center of the Johannes Gutenberg University, Mainz, Germany; UCL Queen Square Institute of Neurology, London, United Kingdom; Vall d’Hebron University Hospital, Barcelona, Spain. Inclusion criteria were a confirmed MS or CIS diagnosis according to the 2017 McDonalds criteria (Thompson et al., 2018), age between 18 and 80 years, multishell dMRI data, and clinical and demographic information. No exclusion criteria for pwMS were added in addition to the inclusion criteria. We included 543 HCs from four sites: 505 from Oslo, 30 from Mainz, and four each from Barcelona and Milan (Fig. 1). The

HCs had no medical issues affecting brain structure and function or any known neurological disorder. Exclusion criteria for the HCs are listed in the supplementary material. The HCs and the pwMS were scanned on the same scanner at each centre using identical parameters (Richard et al., 2018). The project was open for participation in MAGNIMS from January 2021 until June 2022. MRI scans were acquired between October 2014 and September 2021.

Mean age was 40.7 years (range 19–76 years), there were 72.4 % women, 88.8 % had relapsing-remitting MS (RRMS) and mean disease duration was 6.4 years for pwMS. Disability status was measured with EDSS (median 2.0, interquartile range 1.0–3.0) (Table 1).

2.2. Standard protocol approvals, registrations, and patient consents

The project was approved by the Regional Committee for Medical and Health Research Ethics of South East Norway (REK2011–1846A and REK2016/102). Study participants were recruited within the MAGNIMS general framework agreement, with approvals from the regional ethical committees at all local centres. Study participants provided signed informed consent prior to study enrolment at the respective sites according to the Declaration of Helsinki.

2.3. MRI acquisition, processing and data preparation

All centres performed a 3T MRI scan of the brain for all participants. In Supplementary Table 1, details regarding the available DWI sequence parameters are listed. MRI data from 291 pwMS were processed. A total of 40 pwMS or CIS were removed due to MRI artifacts or missing data (28 from IDIBAPS, eight from Oslo, two from both Mainz and London), leaving 251 pwMS (121 from Oslo, 49 from Mainz, 38 from IDIBAPS, 16 from Milan, 15 from Barcelona and 12 from London). One HC from Milan was removed from image processing due to MRI artifacts.

We performed quality control, mostly visual assessments, data inspection and detection of outliers at all stages in the data processing pipeline. Image processing was done using an in-house pipeline in MATLAB (Maximov et al., 2019). In brief, the pipeline includes corrections for noise (Veraart et al., 2016), Gibbs ringing (Kellner et al., 2016), susceptibility-induced and eddy current distortions and motion using FSL function topup (topup - FslWiki (ox.ac.uk)) and eddy (eddy - FslWiki (ox.ac.uk)) (Andersson and Sotiropoulos, 2016) in the case of available opposite phase-encoding images (Jenkinson et al., 2012). Isotropic Gaussian smoothing was carried out with the FSL function *fslmaths* (Jenkinson et al., 2012) with a Gaussian kernel of 1 mm³.

2.4. Imaging derived parameters from multishell diffusion

After the post-processing of the data, the pipeline included dMRI metrics from 11 parameters from the WM. Conventional DTI parameters acquired from b-values ≤ 1000 , included fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), radial diffusivity (RD), which were estimated using DTIFit in FSL (FDT/UserGuide - FslWiki (ox.ac.uk)). RSI parameters (FA fast, FA slow, ADC fast, ADC slow, Cellularity index, neurite density (ND) and rD-FA), were estimated using in-house Matlab tools (White et al., 2014). Cellularity index is the water signal from the spherically restricted diffusion compartment, while neurite density reflects the relative density of neuronal processes (Hope et al., 2019). rD-FA is FA from restricted diffusion compartment (White et al., 2013). ADC fast is a measure of the diffusion of extracellular water, while slow ADC is a measure of the effective diffusion coefficient of intracellular water (Sowa et al., 2019).

The diffusion metric maps were analysed using Tract-based Spatial Statistics (TBSS) (Smith et al., 2006). All volumes were aligned to the FMRIS58_FA template, supplied by FSL (Smith et al., 2004), using a non-linear transformation implemented by FNIRT (Smith et al., 2004). Next, a mean FA image was obtained and thinned in order to create mean FA skeleton. Afterwards, all subject's FA values were projected onto the mean skeleton, by filling the skeleton with FA values from the nearest relevant tract centre. The skeleton-based analysis allows one to minimise confounding effects due to partial voluming and any residual misalignments originating from non-linear spatial transformations. Additionally, the TBSS derived skeleton was used for averaging of diffusion metrics over the skeleton. This procedure was performed for all diffusion metrics using *tbss_non_FA* script from FSL (TBSS/UserGuide - FslWiki (ox.ac.uk)).

To account for site effects across the multi-site MRI dataset, we applied the ComBat harmonization technique (Orlhac et al., 2022). ComBat is a well-established method designed to remove batch effects in high-dimensional data, such as neuroimaging, while preserving biological variability. The adjustment was performed using the ComBat function from the *sva* package in R, with parametric empirical Bayes to stabilize the estimates across sites.

2.5. Statistical analyses

For analyses and illustrations we used R (version 4.4.0) (Team, 2013), mainly adhering to common standard approaches. Diffusion MRI metrics averaged across the WM skeleton were used in paired sample *t*-tests to test for group differences among the pwMS compared with HCs. Pearson's correlation coefficients were estimated where appropriate. We




Fig. 1. Age distribution of the people with MS in A) and healthy controls in B) across all the participating sites.

Table 1

Overview of the demographic and clinical features of the complete cohort.

Centre	Barcelona	IDIBAPS	London	Mainz	Milan	Oslo	All
N - MS	15	38	12	49	16	121	251
N - HC	4	0	0	30	4	505	543
Mean age (SD) at MRI - MS	47.5 (±6.8)	50.3 (±10.8)	35.7 (±8.0)	36.7 (±11.7)	41.6 (±6.2)	39.8 (±8.8)	40.7 (±10.5)
Mean age (SD) at MRI - HC	32.9 (±6.3)	—	—	31.3 (±10.1)	36.5 (±4.0)	44.2 (±10.9)	43.3 (±11.3)
Female - MS	60 %	68.4 %	50 %	63.7 %	56.3 %	60.5 %	72.4 %
Female - HC	50 %	—	—	50 %	75 %	50.2 %	55.7 %
Median EDSS (IQR)	2.0 (1.0–2.5)	3.0 (2.0–4.0)	1.5 (0.5–2.0)	1.0 (1.0–2.5)	4.0 (2.0–6.5)	2.0 (1.5–2.5)	2.0 (1.0–3.0)
Disease duration, mean years (SD)	10.7 (±5.2)	—	1.1 (±0.1)	4.9 (±5.7)	8.8 (±9.2)	6.1 (±4.6)	6.4 (±5.6)
Disease course							
CIS, n (%)	—	—	2 (16.7)	—	—	—	2 (0.8)
RRMS, n (%)	12 (80.0)	28 (73.7)	10 (83.3)	49 (100)	8 (50.0)	116 (95.9)	223 (88.8)
SPMS, n (%)	3 (20.0)	10 (26.3)	—	—	8 (50.0)	5 (4.1)	26 (10.4)
Disease modifying treatment							
No treatment, n (%)	3 (20.0)	12 (31.6)	6 (50.0)	1 (2.0)	5 (31.2)	41 (33.9)	68 (27.1)
Low-efficacy treatment, n (%)	5 (33.3)	11 (28.9)	6 (50.0)	32 (65.3)	4 (25.0)	41 (33.9)	99 (39.4)
Interferon, n (%)	—	2 (5.3)	3 (25.0)	7 (14.6)	—	3 (2.8)	15 (6.0)
Glatiramer acetate, n (%)	1 (6.7)	2 (5.3)	1 (8.3)	5 (10.2)	—	16 (13.2)	25 (10.0)
Dimethyl fumarate, n (%)	2 (13.3)	1 (2.6)	2 (17.0)	17 (34.8)	3 (18.8)	2 (1.7)	27 (10.8)
Teriflunomide, n (%)	2 (13.3)	6 (15.7)	—	1 (2.0)	1 (6.3)	20 (16.5)	25 (10.0)
Daclizumab, n (%)	—	—	—	2 (4.0)	—	—	2 (0.8)
High-efficacy treatment, n (%)	7 (46.7)	15 (39.5)	0 (0.0)	16 (32.7)	7 (43.8)	39 (32.2)	84 (33.5)
Fingolimod, n (%)	2 (13.3)	5 (13.2)	—	5 (10.2)	3 (18.8)	25 (20.7)	40 (15.9)
cladribine (Cladribine), n (%)	—	—	—	1 (2.0)	—	—	1 (0.4)
Alemtizumab, n (%)	1 (6.7)	2 (5.3)	—	2 (4.0)	1 (6.3)	10 (4.0)	16 (6.4)
Natalizumab, n (%)	1 (6.7)	2 (5.3)	—	5 (10.2)	2 (12.6)	4 (3.3)	14 (5.6)
Ocrelizumab, n (%)	2 (13.3)	2 (5.3)	—	2 (4.0)	1 (6.3)	—	7 (2.8)
Rituximab, n (%)	1 (6.7)	3 (7.9)	—	1 (2.0)	—	—	5 (2.0)
Ofatumumab, n (%)	—	1 (0.4)	—	—	—	—	1 (0.4)

MS = multiple sclerosis, HC = healthy control, MRI = magnetic resonance imaging, EDSS = Expanded disability status scale, IQR = inter quartile range, CIS = clinically isolated syndrome, RRMS = relapsing remitting multiple sclerosis, SPMS = secondary progressive multiple sclerosis.




Fig. 2. Visualizing the resulting ComBat-adjusted multishell diffusion weighted parameters across people with MS and healthy controls.

compared the demographic and clinical features between the sites with either ANOVA for continuous variables or Chi-Square Test for categorical variables. To assess clinical correlations we ran linear regression models with only fixed effects, including relevant confounding factors, such as age and sex (Bates et al., 2014). Cohen's *d* was computed when appropriate to evaluate effect size. In the linear models, we also standardized the EDSS, the dMRI metrics and age by using the built in scale function in R using the formula: $x\text{-scaled} = (x - x\text{-mean}) / x\text{-SD}$, to convert each value into a z-score. Linear model setup:

Response variable (EDSS) $\sim$ dMRI metric + age + sex

To account for multiple comparisons, we used a Bonferroni correction, which divides the significance threshold (usually 0.05) by the number of tests performed, thereby reducing the risk of false positives among all significant tests. To investigate the potential interaction between age and each predictor variable, we included an interaction term between age and the predictor variable of interest in our linear regression model.

3. Results

3.1. Case-control differences

We found significant differences between pwMS and HC for most metrics for all sites, except for Cellularity and ADC fast. Fig. 2 and Table 2 summarize the case-control differences in all dMRI metrics. The general diffusion parameters of FA (Cohen's $d = 1.16$) and RD (Cohen's $d = -1.03$) exhibited the highest effect sizes in dMRI metrics between pwMS and HC. The age trajectories for all the diffusion parameters are shown in Fig. 2 and Supplementary Figure 1, showing some outliers and for some diffusion parameters (FA fast and ADC fast) large scanner and

site dependent differences also seen in Supplementary Table 2.

When the analyses were repeated within the Oslo cohort (Supplementary Table 3), the effect sizes were generally larger, especially for FA (Cohen's $d = 2.03$) and RD (Cohen's $d = -1.91$). The Oslo cohort had more robust and pronounced differences, particularly in FA and RD. Despite this, the overall patterns of diffusion abnormalities in pwMS relative to HCs remain consistent across both the entire cohort and the Oslo subgroup (Supplementary Figure 2).

3.2. Clinical correlations with the dMRI features

Linear regression models revealed significant associations between EDSS and FA fast ($\beta = -4.54$, $p = 0.01$) and ADC fast ($\beta = 10.92$, $p = 8.7 \times 10^{-3}$). Lower FA fast and increased ADC fast levels were associated with higher disability. None of the dMRI features remained significant after adjustment for multiple comparisons. Table 3 summarizes the results from linear regression models testing for associations between EDSS and the dMRI metrics, accounting for age, sex. We also explored the clinical correlations with disease course added as a fixed effect in Supplementary Table 4.

4. Discussion

In this cross-sectional study of pwMS collected at six MAGNIMS centres, we have analysed 11 dMRI parameters from multishell diffusion of the brain compared to HCs. Our main findings are significant differences in the WM between pwMS and HC for most dMRI metrics, except for cellularity and fast ADC. Our case-control findings indicate that while multi-site data offers broader generalizability, site-related variations can moderate the magnitude of observed effects. Repeating the analysis within the Oslo cohort showed that the observed trends are not

Table 2
ComBat adjusted dMRI metrics across multiple sclerosis subjects and healthy controls.

	Multiple sclerosis	Healthy controls	<i>t</i>	<i>p</i>	Cohen's <i>d</i>
FA, mean (SD)	0.47 (± 0.04)	0.51 (± 0.02)	13.0	1.6×10^{-31}	1.16
MD, mean $10^{-3}\text{mm}^2/\text{s}$ (SD)	0.77 (± 0.06)	0.73 (± 0.03)	-9.3	2.7×10^{-18}	-0.92
AD, mean $10^{-3}\text{mm}^2/\text{s}$ (SD)	1.21 (± 0.03)	1.21 (± 0.03)	-2.1	0.03	-0.17
RD, mean $10^{-3}\text{mm}^2/\text{s}$ (SD)	0.57 (± 0.07)	0.51 (± 0.03)	-10.5	6.0×10^{-22}	-1.03
Cellularity, mean (SD)	0.27 (± 0.08)	0.28 (± 0.03)	1.1	0.28	0.11
ND, mean (SD)	6.16 (± 2.17)	5.64 (± 0.55)	-3.8	2.2×10^{-4}	-0.40
rD - FA, mean (SD)	0.15 (± 0.01)	0.16 (± 0.01)	4.1	5.2×10^{-5}	0.32
FA fast, mean (SD)	0.41 (± 0.05)	0.40 (± 0.02)	-2.2	0.03	-0.21
FA slow, mean (SD)	0.14 (0 ± 0.01)	0.14 (0 ± 0.01)	2.1	0.04	0.16
ADC fast, mean (SD)	0.13 (± 0.02)	0.13 (± 0.01)	1.3	0.2	0.12
ADC slow, mean (SD)	0.05 (± 0.0)	0.05 (0.0)	7.5	4.2×10^{-13}	-0.65

FA = fractional anisotropy, MD = mean diffusivity, AD = axial diffusivity, RD = radial diffusivity, ND = neurite density, ADC = apparent diffusion coefficient rD - FA = FA for restricted diffusion compartment. Significant differences in bold.

Table 3
Linear regression models showing correlation between EDSS and the ComBat-adjusted dMRI metrics in people with MS.

Linear regression model: EDSS with DWI feature, age and sex					
	Estimates	CI	<i>t</i>	<i>p</i>	<i>p adjusted</i>
FA	-2.17	-6.92 - 2.58	-0.90	0.37	1.0
MD	-1.07	-4.04 - 1.89	-0.71	0.48	1.0
AD	1.27	-4.39 - 6.92	0.44	0.66	1.0
RD	-0.73	-3.21 - 1.74	-0.58	0.56	1.0
Cellularity	1.39	-0.97 - 3.74	1.16	0.25	1.0
ND	0.06	-0.03 - 0.14	1.29	0.20	1.0
rD - FA	1.07	-14.65 - 16.79	0.13	0.89	1.0
FA fast	-4.54	-8.01 - -1.07	-2.58	0.01	0.11
FA slow	-8.73	-21.4 - 3.94	-1.36	0.18	1.0
ADC fast	10.92	2.78 - 19.06	2.64	8.7×10^{-3}	0.10
ADC slow	40.98	-25.71 - 107.68	1.21	0.23	1.0

FA = fractional anisotropy, MD = mean diffusivity, AD = axial diffusivity, RD = radial diffusivity, ND = neurite density, ADC = apparent diffusion coefficient, rD - FA = FA for restricted diffusion compartment. Significant associations in bold.

driven by site-specific confounds, but the effect sizes are amplified when analyzed in a more homogeneous setting. This suggests that scanner and site variability, present in the cohort, may attenuate some of the observed group differences when multiple centers are combined.

Analyses revealed significant associations between EDSS and FA fast and ADC fast in the whole sample, where lower FA fast and increased ADC fast were associated with higher disability. The largest effect sizes for parameters showing significant differences between HC and pwMS were observed in the main diffusion metrics. However, it is important to note that only the advanced multishell diffusion parameters demonstrated significant clinical correlations with EDSS, both in the full cohort and in the Oslo cohort.

Subtle damage outside of visible lesions, in the NAWM, is also prevalent in pwMS (Cercignani and Gandini Wheeler-Kingshott, 2019). Our main finding of significant differences in the WM between pwMS and HCs is therefore not surprising. These findings also agree with previous ex-vivo spinal-cord MS studies (Grussu et al., 2015) and previous studies of brain DTI in MS (Mustafi et al., 2019; Kolasa et al., 2019). Our analysis revealed group differences in metrics assumed to be sensitive to damage to both myelin (e.g. FA, MD, RD, AD) and axons (e.g. rD-FA, ADC), but no difference between cellularity and ADC fast parameters.

Studies have investigated the relation between disability and DTI/dMRI metrics for over two decades (Filippi et al., 2001; Liu et al., 2012; Bergsland et al., 2015; Rimkus Cde et al., 2013; Bezukladova et al., 2020; Tovar-Moll et al., 2009). One study showed association between baseline mean diffusivity values and EDSS at follow-up 4 years later. Brain FA in WM tracts explained 18 % of the variance in future EDSS values (Lopez-Soley et al., 2023). Another study found associations between DTI indices in the corpus callosum and EDSS progression (Kolasa et al., 2019). We also found associations between disability and FA fast and ADC fast. These associations may be used for follow-up and prediction of disease progression in the future, however different methodology e.g. measuring changes in all WM versus specific areas of the WM and using different diffusion techniques is challenging. Future studies should use both longitudinal as well as cross sectional design and include both regional and global dMRI metrics both in GM and WM structures.

The main limitation of this study is the collection of patient samples using non-identical MRI protocols. However, multicentre studies are useful to increase statistical power, although they often increase heterogeneity. Multicentre studies require statistically complex analyses due to site-specific effects and methodological differences (Zhou et al., 2018). These factors can be even more challenging in advanced dMRI research, since added layers of complexity are introduced by differences in the implementation of MRI sequences, diffusion gradient configurations and processing pipelines. We applied harmonized analytical pipelines, both in the imaging analyses and the statistical methods, and we could not identify differences in acquisition parameters that could explain the difference in the resulting data (Maximov et al., 2019). However, an unexpected finding like the lack of difference in cellularity between pwMS and HC, may be related to methodologic factors related to the use of standard dMRI sequences instead of the RSI acquisitions (Pinto et al., 2020). Common statistical and post-processing pipelines are needed to be able to adapt to many different diffusion acquisitions and reduce variability by the abovementioned acquisition variability.

A limitation of this study is the lack of differentiation between the NAWM and WML, since the study's original design did not include FLAIR sequence or lesion masks, and it was not feasible to expand this analysis at a later stage for the whole sample. Future studies of advanced diffusion in NAGM could help elucidate progression of the disease in different forms (i.e. relapsing versus progressive and smouldering MS) (Eshaghi et al., 2018). Furthermore, relying solely on EDSS to measure disability does not capture the full spectrum of MS-related disability. Future studies should also aim to include assessments of cognition, fatigue, and patient-reported outcomes to provide a more comprehensive

evaluation (Giovannoni et al., 2016). A precise characterization of lesions, including lesion types and locations, could yield more findings in future studies. Lastly, the variable number of subjects and controls included at each site may also be a limitation of this study.

5. Conclusions

This study provides insight into microstructural changes both in WM in the brain of pwMS. This adds important information to the growing body of literature of the utility of advanced dMRI in pwMS. Our findings suggest that a majority of multishell diffusion parameters in the WM of the brain significantly differ between pwMS and HCs. Correlations between disability and the imaging parameters were found, but after correcting for multiple testing with Bonferroni correction no significant correlations with disability remained. Restricting the analyses to one clinical cohort, increased the correlations for some diffusion parameters. More studies using similar or improved pipelines for acquisition, post-processing and extraction of dMRI metrics are needed.

CRedit authorship contribution statement

Einar A. Høgestøl: Writing – review & editing, Writing – original draft, Visualization, Supervision, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Daniel A. Rinker:** Writing – review & editing, Writing – original draft, Software, Project administration, Methodology, Investigation, Formal analysis, Conceptualization. **Ivan Maximov:** Writing – review & editing, Writing – original draft, Software, Methodology, Investigation, Formal analysis, Conceptualization. **Piotr Sowa:** Writing – review & editing, Resources, Methodology, Data curation, Conceptualization. **Elisabeth G. Celius:** Writing – review & editing, Resources, Funding acquisition, Data curation. **Tuva R. Hope:** Writing – review & editing, Software, Conceptualization. **Atle Bjørnerud:** Writing – review & editing, Methodology, Conceptualization. **Fuaad M. Sofia:** Writing – review & editing, Methodology. **Eloy Martinez de las Heras:** Writing – review & editing, Resources, Data curation. **Elisabeth Solana:** Writing – review & editing, Resources, Data curation. **Sara Llufrui:** Writing – review & editing, Resources, Funding acquisition, Data curation. **Juan Francisco Corral Gamez:** Writing – review & editing, Resources, Data curation. **Julio Alonso Farre:** Writing – review & editing, Resources, Data curation. **Deborah Pareto:** Writing – review & editing, Resources, Funding acquisition, Data curation. **Sara Collorone:** Writing – review & editing, Resources, Funding acquisition, Data curation. **Elisabetta Pagani:** Writing – review & editing, Resources, Data curation. **Gabriel Gonzalez-Escamilla:** Writing – review & editing, Resources, Data curation. **Sergiu Groppa:** Writing – review & editing, Resources, Funding acquisition, Data curation. **Jaume Sastre-Garriga:** Writing – review & editing, Funding acquisition, Data curation. **Alex Rovira:** Writing – review & editing, Resources, Funding acquisition, Data curation. **Ahmed Toosy:** Writing – review & editing, Resources, Data curation. **Massimo Filippi:** Resources, Funding acquisition, Data curation. **Maria Assunta Rocca:** Writing – review & editing, Supervision, Project administration, Funding acquisition, Data curation. **Lars T. Westlye:** Writing – review & editing, Writing – original draft, Supervision, Software, Resources, Methodology, Investigation, Funding acquisition, Data curation, Conceptualization. **Hanne F. Harbo:** Writing – review & editing, Writing – original draft, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Data curation, Conceptualization. **Mona K. Beyer:** Writing – review & editing, Writing – original draft, Supervision, Project administration, Methodology, Investigation, Conceptualization.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Hanne Flinstad Harbo reports financial support was provided by South Eastern Regional Health Authority of Norway. Sergiu Groppa reports financial support was provided by Deutsche Forschungsgemeinschaft. Einar August Hoegestoel reports a relationship with Biogen that includes: speaking and lecture fees. Einar August Hoegestoel reports a relationship with Merck that includes: funding grants and speaking and lecture fees. Einar August Hoegestoel reports a relationship with Sanofi-Genzyme that includes: board membership and speaking and lecture fees. Piotr Sowa reports a relationship with Merck that includes: speaking and lecture fees and travel reimbursement. Elisabeth Gulowsen Celius reports a relationship with BMS that includes: speaking and lecture fees. Elisabeth Gulowsen Celius reports a relationship with Biogen that includes: speaking and lecture fees. Elisabeth Gulowsen Celius reports a relationship with Janssen that includes: speaking and lecture fees. Elisabeth Gulowsen Celius reports a relationship with Merck that includes: speaking and lecture fees. Elisabeth Gulowsen Celius reports a relationship with Novartis that includes: funding grants and speaking and lecture fees. Elisabeth Gulowsen Celius reports a relationship with Sanofi that includes: funding grants and speaking and lecture fees. Elisabeth Gulowsen Celius reports a relationship with Roche that includes: speaking and lecture fees. Elisabeth Solana reports a relationship with Sanofi that includes: travel reimbursement. Elisabeth Solana reports a relationship with Merck that includes: travel reimbursement. Elisabeth Solana reports a relationship with European Committee for Treatment and Research in Multiple Sclerosis that includes: travel reimbursement. Sara Llufrui reports a relationship with Biogen Idec that includes: consulting or advisory and speaking and lecture fees. Sara Llufrui reports a relationship with Novartis that includes: consulting or advisory and speaking and lecture fees. Sara Llufrui reports a relationship with TEVA that includes: consulting or advisory and speaking and lecture fees. Sara Llufrui reports a relationship with Genzyme that includes: consulting or advisory and speaking and lecture fees. Sara Llufrui reports a relationship with Sanofi that includes: consulting or advisory and speaking and lecture fees. Sara Llufrui reports a relationship with Merck that includes: consulting or advisory and speaking and lecture fees. Deborah Pareto reports a relationship with Novartis that includes: speaking and lecture fees. Deborah Pareto reports a relationship with Sanofi Genzyme that includes: speaking and lecture fees. Deborah Pareto reports a relationship with Biogen Idec that includes: employment. Sara Collorone reports a relationship with Rosetrees Trust that includes: funding grants. Jaume Sastre-Garriga reports a relationship with Biopass that includes: speaking and lecture fees. Jaume Sastre-Garriga reports a relationship with Biogen that includes: speaking and lecture fees. Jaume Sastre-Garriga reports a relationship with Celgene that includes: speaking and lecture fees. Jaume Sastre-Garriga reports a relationship with Sanofi that includes: speaking and lecture fees. Jaume Sastre-Garriga reports a relationship with Merck that includes: speaking and lecture fees. Jaume Sastre-Garriga reports a relationship with Orchid Pharma that includes: speaking and lecture fees. Alex Rovira Canellas reports a relationship with Novartis that includes: board membership and speaking and lecture fees. Alex Rovira Canellas reports a relationship with Sanofi that includes: board membership and speaking and lecture fees. Alex Rovira Canellas reports a relationship with Genzyme that includes: board membership and speaking and lecture fees. Alex Rovira Canellas reports a relationship with Synthetic MR that includes: board membership. Alex Rovira Canellas reports a relationship with Roche that includes: board membership and speaking and lecture fees. Alex Rovira Canellas reports a relationship with Biogen that includes: board membership and speaking and lecture fees. Alex Rovira Canellas reports a relationship with OLEA Medical that includes: board membership. Alex Rovira Canellas reports a relationship with SeroNo that includes: speaking and lecture fees. Alex Rovira Canellas reports a relationship with Teva Pharmaceutical that includes: speaking and lecture fees. Ahmed Toosy reports a relationship with Merck, Biomedica, Biogen Idec and AtTheLimits for speaker expenses. Ahmed Toosy reports that he was UK PI for

two clinical trials sponsored by MEDDAY (MS_ON – NCT0220244 and MS-SPI2 – NCT0220244). Massimo Filippi reports a relationship with Alexion that includes: board membership and consulting or advisory. Massimo Filippi reports a relationship with Almirall that includes: consulting or advisory. Massimo Filippi reports a relationship with Biogen that includes: board membership, consulting or advisory, and speaking and lecture fees. Massimo Filippi reports a relationship with Merck that includes: board membership and speaking and lecture fees. Massimo Filippi reports a relationship with Celgene that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Novartis that includes: board membership, funding grants, and speaking and lecture fees. Massimo Filippi reports a relationship with Roche that includes: consulting or advisory, funding grants, and speaking and lecture fees. Massimo Filippi reports a relationship with Sanofi that includes: board membership and speaking and lecture fees. Massimo Filippi reports a relationship with Bayer that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Chiesi Italia SpA that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Eli Lilly that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Genzyme that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Janssen that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Merck-Serono that includes: funding grants and speaking and lecture fees. Massimo Filippi reports a relationship with Neopharm Gentili that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Novo Nordisk that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Sanofi-Aventis that includes: board membership. Massimo Filippi reports a relationship with Sanofi-Genzyme that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Takeda that includes: speaking and lecture fees. Massimo Filippi reports a relationship with TEVA that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Bristol-Myers Squibb that includes: board membership. Massimo Filippi reports a relationship with Lilly that includes: speaking and lecture fees. Massimo Filippi reports a relationship with Biogen Idec that includes: funding grants. Massimo Filippi reports a relationship with Merck-Serono that includes: funding grants. Massimo Filippi reports a relationship with Italian Ministry of Health that includes: funding grants. Massimo Filippi reports a relationship with Fondazione Italiana Sclerosi Multipla that includes: funding grants. Maria Assunta Rocca reports a relationship with Biogen that includes: consulting or advisory and speaking and lecture fees. Maria Assunta Rocca reports a relationship with Bristol Myers Squibb that includes: consulting or advisory and speaking and lecture fees. Maria Assunta Rocca reports a relationship with Eli Lilly that includes: consulting or advisory. Maria Assunta Rocca reports a relationship with Janssen that includes: consulting or advisory. Maria Assunta Rocca reports a relationship with Roche that includes: consulting or advisory. Maria Assunta Rocca reports a relationship with AstraZaneca that includes: speaking and lecture fees. Maria Assunta Rocca reports a relationship with Bromatech that includes: speaking and lecture fees. Maria Assunta Rocca reports a relationship with Celgene that includes: speaking and lecture fees. Maria Assunta Rocca reports a relationship with Genzyme that includes: employment. Maria Assunta Rocca reports a relationship with Horizon Therapeutics Italy that includes: speaking and lecture fees. Maria Assunta Rocca reports a relationship with Merck Serono SpA that includes: speaking and lecture fees. Maria Assunta Rocca reports a relationship with Novartis that includes: speaking and lecture fees. Maria Assunta Rocca reports a relationship with Sanofi that includes: speaking and lecture fees. Maria Assunta Rocca reports a relationship with TEVA that includes: speaking and lecture fees. Maria Assunta Rocca reports a relationship with MS Society of Canada that includes: funding grants. Maria Assunta Rocca reports a relationship with Italian Ministry of Health that includes: funding grants. Maria Assunta Rocca reports a relationship with Fondazione Italiana Sclerosi Multipla that includes: funding grants. Mona K. Beyer reports a relationship with Novartis that

includes: speaking and lecture fees. Mona K. Beyer reports a relationship with Biogen Idec that includes: speaking and lecture fees. Mona K. Beyer reports a relationship with Biogen that includes: board membership. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Declaration of generative AI and AI-assisted technologies in the writing process

During the preparation of this work the author used ChatGPT 4o in order to improve readability. After using this tool, the author reviewed and edited the content as needed and take full responsibility for the content of the publication.

Acknowledgements

We thank all participants and healthy controls for taking part in our study. We thank Synne Brune, Gro O. Nygaard and Pål Berg-Hansen from Oslo for their valuable contributions to this project.

Data availability statement

The dataset used and analyses during the current study are available from the corresponding author and the respective local project leaders upon on reasonable request.

Funding source

This work was supported by the South Eastern Regional Health Authority of Norway (project number 2017114; HFH), by the German Research Council (Deutsche Forschungsgemeinschaft – DFG; RC-TR-128;SG).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.msard.2025.106435](https://doi.org/10.1016/j.msard.2025.106435).

References

- Andersson, J.L.R., Sotiropoulos, S.N., 2016. An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. *NeuroImage* 125, 1063–1078.
- Barkhof, F., 2002. The clinico-radiological paradox in multiple sclerosis revisited. *Curr. Opin. Neurol* 15 (3), 239–245.
- Bates D., Mächler M., Bolker B., Walker SJapa. Fitting linear mixed-effects models using lme4. 2014.
- Beck, D., de Lange, A.G., Maximov, I.I., Richard, G., Andreassen, O.A., Nordvik, J.E., et al., 2021. White matter microstructure across the adult lifespan: a mixed longitudinal and cross-sectional study using advanced diffusion models and brain-age prediction. *NeuroImage* 224, 117441.
- Bergsland, N., Laganà, M.M., Tavazzi, E., Caffini, M., Tortorella, P., Baglio, F., et al., 2015. Corticospinal tract integrity is related to primary motor cortex thinning in relapsing-remitting multiple sclerosis. *Mult. Scler.* 21 (14), 1771–1780.
- Bezukladova, S., Tuisku, J., Matilainen, M., Vuorimaa, A., Nylund, M., Smith, S., et al., 2020. Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging. *Neurol. Neuroimmunol. Neuroinflamm* 7 (3).
- Brunsing, R.L., Schenker-Ahmed, N.M., White, N.S., Parsons, J.K., Kane, C., Kuperman, J., et al., 2017. Restriction spectrum imaging: an evolving imaging biomarker in prostate MRI. *J. Magnet. Resonance Imaging* 45 (2), 323–336. *JMRI*.
- Cercignani, M., Gandini Wheeler-Kingshott, C., 2019. From micro- to macro-structures in multiple sclerosis: what is the added value of diffusion imaging. *NMR Biomed* 32 (4), e3888.
- Disanto, G., Zecca, C., MacLachlan, S., Sacco, R., Handunnetthi, L., Meier, U.C., et al., 2018. Prodromal symptoms of multiple sclerosis in primary care. *Ann. Neurol.* 83 (6), 1162–1173.
- Eshaghi, A., Marinescu, R.V., Young, A.L., Firth, N.C., Prados, F., Jorge Cardoso, M., et al., 2018. Progression of regional grey matter atrophy in multiple sclerosis. *Brain* 141 (6), 1665–1677.
- Filippi, M., Cercignani, M., Inglese, M., Horsfield, M.A., Comi, G., 2001. Diffusion tensor magnetic resonance imaging in multiple sclerosis. *Neurology* 56 (3), 304–311.
- Geraldes, R., Ciccarelli, O., Barkhof, F., De Stefano, N., Enzinger, C., Filippi, M., et al., 2018. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. *Nature Rev. Neurol.* 14 (4), 199–213.
- Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., et al., 2016. Brain health: time matters in multiple sclerosis. *Mult. Scler. Relat. Disord.* 9 (Suppl 1), S5–S48.
- Grussu, F., Schneider, T., Yates, R.L., Tachrount, M., Newcombe, J., Zhang, H., et al., 2015. Histological metrics confirm microstructural characteristics of NODDI indices in multiple sclerosis spinal cord. In: International society for magnetic resonance in medicine (ISMRM), 23rd annual meeting; May 30–31. Toronto, Ontario, Canada. www.ismr.org.
- Hagler Jr., D.J., Hatton, S., Cornejo, M.D., Makowski, C., Fair, D.A., Dick, A.S., et al., 2019. Image processing and analysis methods for the Adolescent Brain Cognitive Development Study. *NeuroImage* 202, 116091.
- Høgestøl E.A., Kaufmann T., Nygaard G.O., Beyer M.K., Sowa P., Nordvik J.E., et al. Cross-sectional and longitudinal MRI brain scans reveal accelerated brain aging in multiple sclerosis. 2019;10:450.
- Hope, T.R., Selnes, P., Rektorová, I., Anderkova, L., Nemcova-Elfmakova, N., Balázová, Z., et al., 2019. Diffusion tensor and restriction spectrum imaging reflect different aspects of neurodegeneration in Parkinson's disease. *PLoS ONE* 14 (5), e0217922.
- Jelecu, I.O., Palombo, M., Bagnato, F., Schilling, K.G., 2020. Challenges for biophysical modeling of microstructure. *J. Neurosci. Methods* 344, 108861.
- Jenkinson, M., Beckmann, C.F., Behrens, T.E., Woolrich, M.W., Smith, S.M., 2012. FSL. *NeuroImage* 62 (2), 782–790.
- Kato, S., Hagiwara, A., Yokoyama, K., Andica, C., Tomizawa, Y., Hoshino, Y., et al., 2022. Microstructural white matter abnormalities in multiple sclerosis and neuromyelitis optica spectrum disorders: evaluation by advanced diffusion imaging. *J. Neurol. Sci.* 436, 120205.
- Kellner, E., Dhital, B., Kiselev, V.G., Reisert, M., Andersson, J.L.R., Sotiropoulos, S.N., 2016. Gibbs-ringing artifact removal based on local subvoxel-shifts an integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. *Magn. Reson. Med.* 76 (5), 1574–1581.
- Kolasa, M., Hakulinen, U., Brander, A., Hagman, S., Dastidar, P., Elovaaara, I., et al., 2019. Diffusion tensor imaging and disability progression in multiple sclerosis: a 4-year follow-up study. *Brain Behav* 9 (1), e01194.
- Lakhani, D.A., Schilling, K.G., Xu, J., Bagnato, F., 2020. Advanced multicompartiment diffusion MRI models and their application in Multiple sclerosis. *AJNR Am. J. Neuroradiol.* 41 (5), 751–757.
- Le Bihan, D., 1995. Molecular diffusion, tissue microdynamics and microstructure. *NMR Biomed* 8 (7–8), 375–386.
- Liu, Y., Duan, Y., He, Y., Yu, C., Wang, J., Huang, J., et al., 2012. Whole brain white matter changes revealed by multiple diffusion metrics in multiple sclerosis: a TBSS study. *Eur. J. Radiol.* 81 (10), 2826–2832.
- Lopez-Soley, E., Martinez-Heras, E., Solana, E., Solanes, A., Radua, J., Vivo, F., et al., 2023. Diffusion tensor imaging metrics associated with future disability in multiple sclerosis. *Sci. Rep.* 13 (1), 3565.
- Lublin, F.D., Häring, D.A., Ganjgahi, H., Ocampo, A., Hatami, F., Čuklina, J., et al., 2022. How patients with multiple sclerosis acquire disability. *Brain* 145 (9), 3147–3161.
- Maximov, I.I., Alnaes, D., Westlye, L.T., 2019. Towards an optimised processing pipeline for diffusion magnetic resonance imaging data: effects of artefact corrections on diffusion metrics and their age associations in UK Biobank. *Hum Brain Mapp* 40 (14), 4146–4162.
- Mustafi, S.M., Harezlak, J., Kodiweera, C., Randolph, J.S., Ford, J.C., Wishart, H.A., et al., 2019. Detecting white matter alterations in multiple sclerosis using advanced diffusion magnetic resonance imaging. *Neural Regen. Res.* 14 (1), 114–123.
- Orlhac, F., Eertink, J.J., Cottreau, A.S., Zijlstra, J.M., Thiebaut, C., Meignan, M., et al., 2022. A guide to ComBat harmonization of imaging biomarkers in multicenter studies. *J. Nucl. Med.* 63 (2), 172–179.
- Pinto, M.S., Paoletti, R., Billiet, T., Van Dyck, P., Guns, P.J., Jeurissen, B., et al., 2020. Harmonization of Brain diffusion MRI: concepts and methods. *Front Neurosci.* 14, 396.
- Preziosa, P., Pagani, E., Bonacchi, R., Cacciaguerra, L., Falini, A., Rocca, M.A., et al., 2022. In vivo detection of damage in multiple sclerosis cortex and cortical lesions using NODDI. *J. Neurol. Neurosurg. Psych.* 93 (6), 628–636.
- Preziosa, P., Pagani, E., Meani, A., Marchesi, O., Conti, L., Falini, A., et al., 2023. NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis. *J. Neurol.* 270 (2), 810–823.
- Rahmanzadeh, R., Lu, P.J., Barakovic, M., Weigel, M., Maggi, P., Nguyen, T.D., et al., 2021. Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. *Brain* 144 (6), 1684–1696.
- Reisert, M., Kellner, E., Dhital, B., Hennig, J., Kiselev, V.G., 2017. Disentangling micro from mesostructure by diffusion MRI: a Bayesian approach. *NeuroImage* 147, 964–975.
- Richard, G., Kolskär, K., Sanders, A.M., Kaufmann, T., Petersen, A., Doan, N.T., et al., 2018. Assessing distinct patterns of cognitive aging using tissue-specific brain age prediction based on diffusion tensor imaging and brain morphometry. *PeerJ* 6, e5908.
- Rimkus Cde, M., Junqueira Tde, F., Callegaro, D., Otaduy, M.C., 2013. Leite Cda C. Segmented corpus callosum diffusivity correlates with the Expanded Disability Status Scale score in the early stages of relapsing-remitting multiple sclerosis. *Clinics* 68 (8), 1115–1120.
- Rovaris M., Gass A., Bammer R., Hickman S., Ciccarelli O., Miller D., et al. Diffusion MRI in multiple sclerosis. 2005;65(10):1526–32.

- Schiavi, S., Palombo, M., Zacà, D., Tazza, F., Lapucci, C., Castellan, L., et al., 2023. Mapping tissue microstructure across the human brain on a clinical scanner with soma and neurite density image metrics. *Hum Brain Mapp* 44 (13), 4792–4811.
- Schneider, T., Brownlee, W., Zhang, H., Ciccarelli, O., Miller, D.H., Wheeler-Kingshott, C. G., 2017. Sensitivity of multi-shell NODDI to multiple sclerosis white matter changes: a pilot study. *Funct. Neurol.* 32 (2), 97–101.
- Smith, S.M., Jenkinson, M., Johansen-Berg, H., Rueckert, D., Nichols, T.E., Mackay, C.E., et al., 2006. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. *NeuroImage* 31 (4), 1487–1505.
- Smith, S.M., Jenkinson, M., Woolrich, M.W., Beckmann, C.F., Behrens, T.E., Johansen-Berg, H., et al., 2004. Advances in functional and structural MR image analysis and implementation as FSL. *NeuroImage* 23 (Suppl 1), S208–S219.
- Sowa, P., Harbo, H.F., White, N.S., Celius, E.G., Bartsch, H., Berg-Hansen, P., et al., 2019. Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis. *Mult. Scler.* 25 (5), 687–698.
- Team R.C. R: a language and environment for statistical computing. 2013.
- Thompson, A.J., Banwell, B.L., Barkhof, F., Carroll, W.M., Coetsee, T., Comi, G., et al., 2018. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol* 17 (2), 162–173.
- Tovar-Moll, F., Evangelou, I.E., Chiu, A.W., Richert, N.D., Ostuni, J.L., Ohayon, J.M., et al., 2009. Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T. *AJNR Am. J. Neuroradiol.* 30 (7), 1380–1386.
- Veraart, J., Fieremans, E., Jelescu, I.O., Knoll, F., Novikov, D.S., 2016. Gibbs ringing in diffusion MRI. *Magn. Reson. Med.* 76 (1), 301–314.
- White, N.S., Leergaard, T.B., D’Arceuil, H., Bjaalie, J.G., Dale, A.M., 2013. Probing tissue microstructure with restriction spectrum imaging: histological and theoretical validation. *Hum Brain Mapp* 34 (2), 327–346.
- White, N.S., McDonald, C., Farid, N., Kuperman, J., Karow, D., Schenker-Ahmed, N.M., et al., 2014. Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging. *Cancer Res.* 74 (17), 4638–4652.
- Yoon, K., Archer, D.B., Clarke, M.A., Smith, S.A., Oguz, I., Cutter, G., et al., 2022. Transcallosal and corticospinal white matter disease and its association with motor impairment in multiple sclerosis. *Front. Neurol.* 13, 811315.
- York, E.N., Meijboom, R., Thrippleton, M.J., Bastin, M.E., Kampaite, A., White, N., et al., 2022. Longitudinal microstructural MRI markers of demyelination and neurodegeneration in early relapsing-remitting multiple sclerosis: magnetisation transfer, water diffusion and g-ratio. *NeuroImage Clin.* 36, 103228.
- Zhang, H., Schneider, T., Wheeler-Kingshott, C.A., Alexander, D.C., 2012. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. *NeuroImage* 61 (4), 1000–1016.
- Zhou, X., Sakaie, K.E., Debbs, J.P., Narayanan, S., Fox, R.J., Lowe, M.J., 2018. Scan-rescan repeatability and cross-scanner comparability of DTI metrics in healthy subjects in the SPRINT-MS multicenter trial. *Magn Reson Imaging* 53, 105–111.